Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02332798 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02332798 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 39 participants.
The verdict
NCT02332798, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
Interventions
- DRUG Placebo
- DRUG PF-04958242
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-01-06 |
| Est. Completion | 2015-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02332798
The ClinicalTrials.gov registry entry for NCT02332798 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02332798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02332798 about?
NCT02332798 is a clinical study titled "Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia". This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
What is the current status of trial NCT02332798?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2015-01-06. Estimated completion is 2015-04-15.
What interventions are being tested in trial NCT02332798?
The interventions under investigation include: Placebo (DRUG), PF-04958242 (DRUG).
Who is sponsoring clinical trial NCT02332798?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.